PathMaker Neurosystems Inc. Announces the Addition of Deborah DiSanzo to the Company’s Board of Directors
Boston, MA and Paris, France (January 11, 2016) — PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing non-invasive neurotherapy systems for the treatment of patients with neuromotor disorders, has named Deborah DiSanzo, M.B.A., to the Company’s Board of Directors.
Deborah DiSanzo brings more than 30 years of experience building and managing organizations at the interface of technology and healthcare. She was recently recruited to lead IBM’s Watson Health as General Manager of the newly formed business unit focused on bringing cognitive computing to healthcare. Prior to joining IBM’s Watson Health, she was CEO of Philips Healthcare, which she ran since 2012. Earlier in her career, she was at Heartstream and at Hewlett-Packard. Deborah completed her M.B.A. at Babson’s Haas School of Business.
“We are truly pleased to have someone with the industry leadership background such as Deborah join our Board,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “This is a pivotal year for PathMaker, as the Company is making significant progress advancing our platforms into clinical development. We believe that Deborah’s valuable expertise and industry knowledge will help us achieve our objective of bringing a new generation of non-invasive neurotherapy systems to market.”
“I am delighted to be working with the PathMaker team,” said Deborah DiSanzo. “PathMaker is developing a groundbreaking approach to treating patients with neuromotor disorders, and their technology promises to transform the way that these patients are treated.”
About PathMaker Neurosystems Inc.
PathMaker Neurosystems Inc. is a clinical-stage neuromodulation company founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) to patients with neuromotor disorders. With offices in Boston (US) and Paris (France), PathMaker is moving forward a trans-Atlantic strategy to rapidly bring to market novel approaches to treating patients. More than 28 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders. The non-invasive systems that PathMaker is developing are opening up a new era of non-invasive neurotherapy for patients suffering from chronic conditions.
Press Contact: Don Goncalves, Tiziani Whitmyre, 781.793.9380, email@example.com